421 Initial results of a phase 1 trial of RP2, a first in class, enhanced potency, anti-CTLA-4 antibody expressing, oncolytic HSV as single agent and combined with nivolumab in patients with solid tumors

• Anna Olsson-Brown,
• Joseph Sacco,
• Mark Middleton,
• Kevin Harrington,
• Robert Coffin,
• Howard Kaufman,
• Suzanne Thomas,
• Praveen Bommareddy,
• Francesca Aroldi,
• Pablo Nanclares,
• Lavita Menezes,
• Selda Samakoglu

Affiliations

Anna Olsson-Brown

2University of Liverpool, Wirral, UK

Joseph Sacco

2University of Liverpool, Wirral, UK

Mark Middleton

2Churchill Hospital, Oxford, UK

Kevin Harrington

Aff11 grid.18886.3f0000000112714623The Institute of Cancer Research/The Royal Marsden Hospital London UK

Robert Coffin

Aff14 grid.417886.40000 0001 0657 5612Amgen Woburn MA USA

Howard Kaufman

Aff15 grid.430387.b0000000419368796Rutgers Cancer Institute of New Jersey New Brunswick NJ USA

Suzanne Thomas

Aff1 Replimune Inc 18 Commerce Way 01801 Woburn MA USA

Praveen Bommareddy

10Replimune, Woburn, MA, USA

Francesca Aroldi

1University of Oxford, Oxford, UK

Pablo Nanclares

3The Institute of Cancer Research, London, UK

Lavita Menezes

4Replimune Inc., Woburn, MA, USA

Selda Samakoglu

4Replimune Inc., Woburn, MA, USA